Лучевая терапия средними фракциями периферического немелкоклеточного рака легкого
Диссертация
Ведущим методом в лечении рака легкого остается хирургический — развитие хирургической техники и анестезиолого-реаниматологического пособия позволило расширить показания к хирургическому лечению. Несмотря на достигнутый прогресс, лишь 24,9% от всех вновь выявленных в 2010 г. больных раком нижних дыхательных путей (42,5% больных 1-Ш стадиями) получили специализированное лечение (из них: только… Читать ещё >
Список литературы
- Акимов A.A. Радиобиологическая оптимизация лучевой терапии злокачественных опухолей. // Материалы невского радиологического форума. -Санкт-Петербург, 2005. -С.352−353.
- Березкин Д.П., Филатов В. Н. Статистический анализ с помощью методов углового преобразования эффективности лечения больных злокачест-веннми опухолями // Вопросы онкологии. -1985. -№ 1. -С. 18−25.
- Васильев В.Н. Использование поля точечного мононаправленного источника для расчета доз в органах пациента при лучевой терапии. // Мед. Техника. -1992. № 6. — С.14−15.
- Давыдов М.И., Аксель Е. М. Статистика злокачественных новообразований в России и странах СНГ в 2010г. // Москва, РОНЦ, 2012 г.
- Голдобенко Г. В., Канаев C.B. Современные подходы к использованию лучевой терапии у больных немелкоклеточным раком легкого. // Вопросы онкологии. -1998. -Т.44. -№ 5. -С.623−628.
- Костылев В.А. Анализ состояния радиационной онкологии в мире и России. // Мед. физика. -.2009. -№ 3 (43). -С.5−20.
- Мардынский Ю.С., Золотков А. Г., Кудрявцев Д. В. Значение лучевой терапии в лечении рака легкого. // Вопросы онкологии. -2006. -Т.52. -№.5. -С. 499−504.
- Мардынский Ю.С., Гулидов И. А., Золотков А. Г., Иванова И. Н., Кудрявцев Д. В., Рагулин Ю. А., Гоголин Д. В., Курсова J1.B. Ускоренные режимы лучевой терапии рака легкого. // Радиационная онкология и ядерная медицина. -2011. -№ 1. -С.14−17.
- Мус В. Ф., Сокуренко В. П., Лубенец Э. Н. Стандартизация лучевой терапии (ЛТ) неоперабельного рака легкого. Актуальные вопросы медицинской радиологии. // Материалы межрегиональной конференции. -Челябинск, 1997. -С. 110−111.
- Пирогова H.A. Подход к оценке кривых выживаемости у онкологических больных. // Сб. тез. докл. Медицинская физика 97. -Обнинск, 1997. -С.11.
- Полоцкий Б.Е. Хирургическое лечение немелкоклеточного рака легкого. // Дисс. доктора мед. наук. -Москва, 1995 г.
- Ратнер Т.Г., Фадеева М. А. Техническое и дозиметрическое обеспечение диистанционной гама-терапии. -М.: Медицина, 2009. -161 с.
- Рудерман А.И., Вайнберг М. Ш., Жолкивер К. И. Дистанционная гамма-терапия злокачественных опухолей. -М.: Медицина, 1977. -172 с.
- Харченко В.П., Кузьмин И. В. Рак легкого. // М.: Медицина, 1994.450 с.
- Харченко В.П., Сотников В. М., Паньшин Г. А., Ильин М. А. и со-авт. Проблема дозы в современной лучевой терапии немелкоклеточного рака легкого. // Мед. радиология и рад. безопасность. -2007. -№ 3. -С.61−70.
- Ярмоненко С.П., Вайнсон A.A. Радиобиология человека и животных. -М.: Высшая школа, 2004 г. -549 с.
- Ahn S., Kahn D.A., Zhou S. et al. Dosimetric Parameters Predictive for Radiation Injury. // Int.J.Rad.Oncol. Biol.Phys. -2003. -V.57. -N.2. -A2123.
- Anscher MS Marks L.B., Shafram T.D. et al. Risk of long-term complications after TGF-(31-guided very-high-dose thoracic radiotherapy. // Int.J.Rad.Oncol. Biol.Phys. -2003. -V.56. -N.4. -P.988−995.
- Armstrong JG, Zelefsky MJ, Leibel SA, Burman C, Han C, Harrison LB, Kutcher GJ, Fuks ZY. Strategy for dose escalation using 3-dimensional conformai radiation therapy for lung cancer. // Ann. Oncol. -1995. -V.6(7). -P.693−697.
- Arriagada R., Le Chevalier T., Quox E. et al. ASTRO plenary: effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. // Int.J.Rad.Oncol. Biol. Phys. -1991. -V.20. -P.l 183−1190.
- Ashish B. et al. Predictors of acute esophagitis in patients with non-small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery. // Int.J.Rad.Oncol. Biol.Phys. -2004. -V.60. -P.l 106−12.
- Belderbos JSA., De Jaeger K., Heemsbergen W.D. et al. First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimentional conformai radiotherapy. //Radiother. Oncol. -2003. -V.66. -P.l 19−126.
- Brade A., Leung S., Sun A. et al. An Accelerated Hypofractionated Radiation Treatment Regimen For Early Stage Non-Small Cell Lung Cancer. // Radiother. and Oncol. -2004. -V.72. -Suppl. -A. 105.
- Brindle JS, Shaw EG, Su JQ, et al. Pilot study of accelerated hyperfractionated thoracic radiation therapy in patients with unresectable stage III non-small cell lung carcinoma. // Cancer. -1993. -V.72(2). -P.405−409.
- Burman C., Kutcher G.J., Emami B. et al. Fitting of normal tissue tolerance data to an analytic function. // Int.J.Rad.Oncol. Biol.Phys. -1991. -V.20. -P.1183−1190.
- Caglar H., Othus M., Allen A. Esophagus in-field: A new predictor for esophagitis. // Radiotherapy and Oncology. -2010. -V.97. -P.48−53.
- Cakir S., Egehan I. A randomized clinical trial of radiotherapy plus cisplatin versus radiotherapy along in stage III NSCLC. // Lung Cancer. -2004. -V43. -P.309−316.
- Campeau M.P., Herschtal A., Wheeler G. Local control and survival following concomitant chemoradiotherapy in inoperable stage I Non-Small-Cell Lung Cancer. // Int. J. Rad. Oncol. Biol. Phys. -2009. -V.74. -N.5. -P. 1371−1375.
- Coy P. et al. The role of curative radiotherapy in the treatment of lung cancer// Cancer. -1980. -V.45. -P.698−702.
- Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatmentof cancer (EORTC). // Int. J. Rad. Oncol. Biol. Phys. -1995. -V.31. -N.5. -P.1341−1346.
- Cutler S. J. J., Ederer F. Maximum utilisation of life table method in analyzing survival // J. Chron. Dis. -1958. -V.8. -P.699−712.
- Deschavanne P.J., Fertil B. A review of human cell radiosensitivity in vitro. // Int.J.Rad.Oncol. Biol.Phys. -1996. -V.34. -Nl. -P.251−266.
- De Jager K., Seppenwoolde Y., Boerishma L.J. et al. Pulmonary fanction following high-dose radiotherapy of non-small-cell lung cancer. // Int.J.Rad.Oncol. Biol.Phys. -2003. -V.55. -N5. -P.1331−1340.
- Dillman R.O., Seagren S.L., Propert K.J.et al. A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III non-small cell lung cancer. //N Engl J Med. -1990. -V.323. -P.940−945.
- Emami B., Lyman J., Broun A. et al. Tolerance of normal tissue to therapeutic irradiation. //Int.J.Rad.Oncol. Biol.Phys. -1991. -V.21. .N.1, P.109−122.
- Fowler J.F. The linear-quadratic formula and progress in fractionated radiotherapy. // Br. J. Radiol. -1989. -V.62. -P.679−694.
- Fowler J.F., Wolfgang A. T., Fenwick J.D. et al. A challenge to traditional radiation oncology. // Int.J.Rad.Oncol. Biol.Phys. -V.60. -N.4. -P. 12 411 256.
- Fujimoto N., Sumi M., Ito Y. et al. Radiotherapy for non-small-cell lung cancer: Relationship between loco-regional failure and irradiated volume. // ASCO. -2005. -Abstract 7263.
- Grills I.S., Fitch D., Goldstein N. Clinicopathologic analysis of microscopic extension in lungadenocarcinoma: defining clinical target volume for radiotherapy. // Int.J.Rad.Oncol. Biol.Phys. -2007. -V.69. -N.2. -P.334−341.
- Groen H.J. et al. Continuosly infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a muticenter phase III study. //Ann.Oncol. -2004. -V.15 (8). -P. 1298−1299.
- Hara R. Jtami J. Clinical outcomes of Stereotactic High Dose Irradiation of Lung Tumors Under Respiratory Gating. // Int.J.Rad.Oncol. Biol.Phys. -2003.-V.57. -N.2.-A2119.
- Hernando M.L., Marks L.B., Bentel G.C. et al. Radiation -induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. //Int. J. Rad. Oncol. Biol. Phys. -2001. -V.51. -N.3. -P.650−659.
- Herrman T., Baumann M., Voigtmann L. et al. Effect of irradiated volume on lung damage in pigs. // Radiother. Oncol. -1997. -V.44. -P.35−40.
- Hof H., Herfarth K.K., Munter M. et al. Stereotactic single-dose radiotherapy of stage I non-small-cell lung cancer. // Int.J.Rad.Oncol. Biol.Phys. -2003. -V.56. -N.2. -P.335−341.
- Hayman J.A., Martel M.K., Ten Haken R.K. et al. Dose escalation study non-small cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. // J.Clin. Oncol. -2001. -V.19. -P. 127−136.
- Hopewell W., Trott K.R. Volume effect in radiobiology as applied to radiotherapy. //Radiother. Oncol. -2000. -V.56. -N.2. -P.283−288.
- Ikeda N., Tsuboi M., Hiyoshi T. et al. A clinicopathological study of resected adenocarcinoma less than 2 cm in size. // Lung Cancer. -2003. -V.41. -Suppl.3. -P.51.
- Jeremic B., Milicic B., Dagovic A. et al. Radiation therapy with and without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of head and neck. // J.Clin. Oncol. -2004. -V.22. -N.17 -P.3540−3548.
- Joiner M.C., Bentsen S.M. Time-dose relationship: the linear-quadratic approach. In Steel G.G. (ed.) Basic Clinical Radiobiology, Third edition.: Hodder Arnold, 2002. -P.121−133
- Karasawa K., Hanyu N., Kawakami M., Harada K. A prospective study of non-coplanar conformal radiotherapy for stage INSCLC using middle-sized fractions. // ASCO 2005. -Abstract 7280.
- Koukourakis M., Hlouverakis G., Kosma L. et al. The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung cancer. // Int.J.Rad.Oncol. Biol.Phys. -1996. -V.34, -N.2, -P.23−33.
- Krol A.D.G., Aussems P. Noordic E.M. et al. Local irradiation alone for peripheral stage I lung cancer: Could we omit the elective regional nodal irradiation. Int.J.Rad.Oncol. Biol. Phys- 1996- V.34:N2. P. 297−302.
- Kupelian PA, Komaki R, Allen P. Prognostic factors in the treatment of node-negative nonsmall cell lung carcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys- 36(3):607−13 1996.
- Liao Y., Joiner M., Huang Y., Burmeister J. Hypofractionation: What Does It Mean For Prostate Cancer Treatment? // Int. J. Radiat. Oncol. Biol. Phys. -2010. -V.76. -N.l. -P.260−268.
- Libshitz H, Southard M. Complication in radiation therapy: The thorax. // Semin.Roentgenol. -1974. -V.9. -P.41−49.
- Lichter A.S., Sandler H.M., Robertson J.M. et al. Clinical experience with three-dimentional treatment planning. // Sem. Rad. Oncol. -1992. -V.2. -P.257−266.
- Lichter A.S. Three dimentional radiotherapy planning. // ASCO Educational Book, 2004. -P.300−304.
- Le Chevalier T., Arriagada R., Quoix E., et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer. // J.Natl. Cancer Inst. -1991. -V.83. -P.417−423.
- Liu H.H., Xiaochung Wang, Lei Dong et al. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. // Int.J.Rad.Oncol. Biol.Phys. -2004. -V.58. -N.4. -P. 1268−1279.
- Liu H.H., Koch N., Starcschall G. et al. Evaluation of internal lung motion for respiratory-gated radiotherapy using MRI: Part II margin reduction of internal target volume. // Int.J.Rad.Oncol. Biol.Phys. -2004. -V.60. -N.5. -P. 14 731 483.
- Mackillop W.J. Bates J.H.T., O’Sullivan B. et al. The effect of delay in treatment on local control by radiotherapy. // Int.J.Rad.Oncol. Biol.Phys. -1996. -V.34. -N.l.-P. 243−250.
- Martel M.K., Strawderman M., Hasuka M.B. et al. Volume and dose parameters for survival of non-small cell lung cancer patients. // Radiother. Oncol. -1997. -V.44. -P.23−29.
- Martel M.K., Ten Haken R.K., Hasuka M.B. et al. Estimation of tumor control pro-bability parameters from 3-D dose distributions of non-small cell lung cancer patients. //Lung Cancer. -1999. -V.24. -N.l. -P.31−37.
- Martin C., Romero S., Sanchez-Paya J. et al. Bilateral lymphocytic alveolitis: a common reaction after unilateral thoracic irradiation. // Eur. Respir. J. -1999- V.13. -P.727−732.
- Mehta Vivek, M.D. Radiation pneumonitis and pulmonary fibrosis in non-small cell lung cancer: Pulmonary function, prediction, and prevention. // Int.J.Rad.Oncol. Biol.Phys. -2005. -V.63. -P.5−24.
- Mehta M., Scrimger R., Mackie R. et al. A new approach to dose escalation in non-small cell lung cancer. // Int.J.Rad.Oncol. Biol.Phys. -2001. -V.49. -P.23−33.
- Miller K.L., Timothy D. Bronchial stenosis: An underreported complication of high-dose external beam radiotherapy for lung cancer. // Int.J.Rad.Oncol. Biol.Phys. -2005. -V.61. -P.64−69.
- Miyamoto T., Yamamoto N., Nishimura H. et al. Carbon ion therapy for stage I non-small cell lung cancer. // Radiother. Oncol. -2003. -V.66. -P.127
- Moctary M., Bach P.B., Tietjen P.A., et al. Bronchiolitis obliterance organizing pneumonia in cancer: a case series. // Resp. Med. -2002. -V.96. -P.280−286.
- Mountain C.F. Lung cancer staging classification. // Clin. Chest Med. -1993. -V.14. -P.45−53.
- Murshed H., Liu H.H., Liao Z. et al. Dose and volume reduction for normal lung using intencity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. // Int.J.Rad.Oncol. Biol.Phys. -2004. -V.58. -N.4. -P. 1258−1267.
- Nagata Y., Takayama K., Aoki T. et al. Clinical Outcome of 3-D con-formal Hypofractionated High-Dose Radiotherapy for Primary and Secondary Lung Cancer using a Stereotactic Technique. // Int.J.Rad.Oncol. Biol.Phys. -2003. -V.57. -N.2. -Suppl. -A. 1032.
- Nakayama H., Sugahara S., Tokita M., Satoh H. et al. Proton beam therapy for patients with medically inoperable stage I non-small cell lung cancer at the University of Tsukuba. // Int. J. Rad. Oncol. Biol.Phys. -2010. V.78. -N.2. -P.467−471.
- Nihei K., Ogino T., Ishikura S. et al. High dose proton beam therapy (PBT) for stage I non-small cell lung cancer (NSCLC) // ASCO, 2005. -Abstract 7226.
- Norihiko Ikeda, Masahiro Tsuboi, Toshimitsu Hiyoshi et al. A clinicopathological study of resected adenocarcinoma less than 2 cm in size. // Lung Cancer. -2003. -V.41. -Suppl.3. -P. 51.
- NSCLC Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. // BMJ. -1995. -V.311. -P.899−909.
- Onimaru R., Shirato H., Shimizu S. et al. Tolerance of organs at risk in small volume hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. // Int.J.Rad.Oncol. Biol.Phys. -2003. -V.56. -N.l. -P.126−135.
- Ohtsuka T., Nomori H., Horio H. et al. Radiological examination for peripheral lung cancers and benign nodules less then 10 mm. // Lung Cancer. -2003. -V.42.-N.3.-P.291−296.
- Oldham M., leturneau D., Watt L. et al. Cone-beam-CT guided radiartion therapy: A model for on-line application. // Radiother. Oncol. -2005. -V75. -N3. -P.271−278.
- Pignon T., Gregor A., Koning C.S. et al. Age has no impact on acute and late toxicity of curative thoracic radiotherapy. // Radiother. Oncol. -1998. -V.46. -P.239−248.
- Ramesh Gopal, Tucker S. L., Komaki R. et al. The relationship between local dose and loss of function for irradiated lung. // Int. J. Radiat. Oncol. Biol. Phys. -2003. -V. 56. -P.106−113.
- Rene W.M. Underberg, M.D., Frank J. L. et al. Benefit of respiration-gated stereotactic radiotherapy for stage I lung cancer: An analysis of 4DCT datasets. // Int. J. Radiat. Oncol. Biol. Phys. -2005. -V.62. -P.554−560.
- Robertson JM, Ten Haken RK, Hazuka MB, et al. Dose escalation for non-small cell lung cancer using conformal radiation therapy. // Int. J. Radiat. Oncol. Biol. Phys. -1997. -V.37. -N.5. -P.1079−1085.
- Rosental S.A., Curran W.J., Herbert S.H. et al. Clinical Stage II Non-Small Cell lung Cancer Treated with Radiation therapy Alone. The significance of clinically Staged Ipsilateral Hilar Adenopathy (NI Disease) // Cancer. -1992. -V.70. -P.2410−2417.
- Rosenzweig K.E., Yorke E., Jacson A et al. Results of Phase I Dose Escalation Study in the Treatment of Inoperable Non-Small Cell Lung Cancer. // Int. J. Rad. Oncol. Biol. Phys. -2003. -V.57. -N.2. -Suppl. -A2125.
- Rossman I. Presidental report ti the American Geriatrics, May, 1982-April 30,1983 // J. Amer. Soc. -1984.-V.32. -N.l. -P.80.
- Ruiz-Torres A. Biological age and ageing risk factors. // Madrid: Tech. Publications, 1987. -pp.322.
- Saunders M.I., Lyn E., Pigott K. et al. Experience of a dose escalation study using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekendless) in non-small cell lung cancer. // Lung Cancer. -1997. -V.18. -P. 123 124.
- Seppenwoolde Y., Engelsman M., De Jager K. et al. Optimizing radiation treatment plans for lung cancer using lung perfusion information. // Radiother. Oncol. -2002. -V.63. -N.2. -P.165−177.
- Seppenwoolde Y., Lebesque JV, de Jaeger K. et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. // Int.J.Rad.Oncol. Biol.Phys. -2003. -V.55. -N.3. -P.724
- Schwarz M., Marcus A., Lebesque J.V., et al. Dose geterogeneity in the target volume and IMRT to escalate the dose in the treatment of non-small cell lung cancer. // Int. J. Radiat. Oncol. Biol. Phys. -2005. -V.62. -P.561−570.
- Shaake-Koning C., Van Den Bogaert W., Dalesio O et al. Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-SmallCell lung Cancer. //N. Engl. J. Med. -1991. -V.326. -P.524−530.
- Shaw EG Thoracic radiation therapy for unresectable non-small-cell lung cancer. // ASCO 30-th Annual meeting educational Book, 1994. -P. 196−202.
- Slotman B.J., Antonisse I.E., Njo K.H. Limited field irradiation in early stage (T1−2N0) non-small cell lung cancer. // Radiother. Oncol. -1996. -V.31. N.l. -P.41−44.
- Sobin L. H., Wittekind Ch. (eds.).//UICC: TNM Classification of Malignant Tumors. 6th edition. -New York.: Wiley, 2002. -pp.239.
- Stroom J., Blaauwgeers H., Van Baardwijk A. Feasibility of pathology-correlated lung imaging for accurate target definition of lung tumors. // Int. J. Radiat. Oncol. Biol. Phys. -2007. -V.69. -N.l. -P.267−275.
- Therasse P., Arbuck S.G., Eisenhauer E.A. et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. // Journal of the National Cancer Institute. -2000. -V.92. -N.3. -P.205−216.
- Timmerman R., McGarry R., Yiannoutsos C. et al. Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer. // J. Clin. Oncol. -2006. -V.24. P.4833−4839.
- Timmerman R.D., Papiez L., McGarry R et al. Extracranial Sterotactic Radioablation: Results of a Phase I Study in Stage I Non-Small Cell Lung Cancer. // Int. J. Rad. Oncol. Biol. Phys. -2003. -V.57. -N.2. -A1033.
- Trott K.R. Chemoradiotherapy interactions and lung toxicity. // Ann Oncol. -1999. -V.10. -Suppl.5. -S77−81.
- Tubiana M., Dutrex J., Wambersie A. Introduction to Radiobiology. //Tailor&Francis, London etc., 1990. -pp.371.
- Uematsu M., Shioda A., Taira H. et al. CT-guided Stereotactic Radiation Therapy (SRT) for Stage I Non-Small Cell Lung Cancer (NSCLC):8 Year results of 50 Initial Patients. // Int.J.Rad.Oncol. Biol.Phys. -2003. -V.57. -N.2. -A1034.
- Van Houtte P. Progress in radiotherapy in lung cancer: An overview. // The journal of the International Association for the study of Lung Cancer. -2000. -V. 29. -N.2. -P.176.
- Wigren T. Confirmation of a prognostic index for patients with inoperable non-small cell lung cancer. Radiother. Oncol. 1997.-V44. P.9−15.
- Williams M.V., Summers E7T., Drinkwater K. et al. Radiotherapy Dose Fractionation, Access and Waiting Times in the Countries of the UK in 2005. // Clinical Oncology. -2007. -V.19. -P.273−286.
- Witers H.R., Thames H.D., Peters L.J. A new isoeffect curve for change in dose per fraction. // Radiother. Oncol. -1983. V.I., P. 187−191.
- Witers H.R., Taylor J.M.G., Maciewski B. Treatment volume and tissue tolerance. // Int. J. Rad. Oncol. Biol. Phys. -1988. -V.14. -P.751−759.
- Witers H.R., Taylor J.M.G., Maciewski B. The hazard of accelerated tumor clonoren repopulation during radiotherapy. // Acta Oncol. -1988. -V.47. -P.131−146.
- Zhu J., Zhang Z., Li B. et al. Analysis of acute radiation-induced esoph-agitis in non-small-cell-lung cancer patients using the Lyman NTCP model. // Radiotherapy and Oncology. -2010. -V.97. -P449−454.